Skip to main content
. 2022 Nov 3;40(11):1551–1562. doi: 10.1038/s41587-022-01530-9

graphic file with name 41587_2022_1530_Figo_HTML.jpg

Olivia Cavlan, chief corporate development and strategy officer, Alchemab Therapeutics.

Ian Cumming